Long-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus

Andersohn, Frank; Schade, R; Suissa, Samy; Garbe, Edeltraut

doi:10.1176/appi.ajp.2008.08071065

Cited by 257 publications

(213 citation statements)

References 39 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…An association between depression and diabetes has been well recognized as the prevalence of depression is doubled in type 2 diabetics compared with the general population (1)(2)(3). However, treatment with currently available antidepressant drugs can increase the risk of developing type 2 diabetes among those at high risk for the disease (4)(5)(6). Thus, characterization of the biological factors for comorbidity of depression and diabetes and identification of innovative therapeutic targets for the treatment of depression, especially for those with comorbid diabetes, are urgently needed.…”

mentioning

confidence: 99%

Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity

Liu¹,

Guo²,

Zhang³

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

149

162

View full text Add to dashboard Cite

Depression is a debilitating mental illness and is often comorbid with metabolic disorders such as type 2 diabetes. Adiponectin is an adipocyte-derived hormone with antidiabetic and insulin-sensitizing properties. Here we show that adiponectin levels in plasma are reduced in a chronic social-defeat stress model of depression, which correlates with decreased social interaction time. A reduction in adiponectin levels caused by haploinsufficiency results in increased susceptibility to social aversion, "anhedonia," and learned helplessness and causes impaired glucocorticoid-mediated negative feedback on the hypothalamic-pituitary-adrenal (HPA) axis. Intracerebroventricular (i.c.v.) injection of an adiponectin neutralizing antibody precipitates stress-induced depressive-like behavior. Conversely, i.c.v. administration of exogenous adiponectin produces antidepressantlike behavioral effects in normal-weight mice and in diet-induced obese diabetic mice. Taken together, these results suggest a critical role of adiponectin in depressive-like behaviors and point to a potential innovative therapeutic approach for depressive disorders.

show abstract

mentioning

confidence: 99%

Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity

Liu¹,

Guo²,

Zhang³

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

149

162

View full text Add to dashboard Cite

show abstract

“…In particular, fluvoxamine has shown the strongest association with the development of DM2, obtaining an odds ratio of 9.05 (95% CI 1.08-75.58) in a recent large case-control study by Andersohn et al [75] . On the other hand, sertraline has been reported to be associated with significant reductions in glycated [58] Paroxetine, sertraline, fluoxetine, fluvoxamine and citalopram…”

Section: Dysglycemiamentioning

confidence: 97%

“…Although this SSRI tends to be associated with increased risk of DM2 and obesity [75] , in short-term uses, it has proved to be innocuous, or even beneficial regarding glucose homeostasis: in a 5-week double-blind, randomized study by WeberHamann et al [80] on non-diabetic patients with MDD, paroxetine was associated with improved insulin sensitivity. Paile-Hyvärinen et al [81] echoed these findings in a 10-week, single-blind study on 15 patients with MDD.…”

Section: Prospective Cohort Study Including 97 Female Patients With Gmentioning

confidence: 99%

Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors: are the metabolic syndrome and an increase in cardiovascular risk unavoidable?

Chávez-Castillo¹,

Ortega²,

Nava³

et al. 2018

View full text Add to dashboard Cite

Depression is one of the most common psychiatric disorders, and has become an epidemic in modern medical practice; notorious for frequently co-occurring with multiple comorbidities, especially cardiovascular disease (CVD), type 2 diabetes mellitus (DM2), and its various risk factors comprised in the metabolic syndrome (MS). Selective serotonin reuptake inhibitors (SSRIs) are the most widely used class of psychotropic drugs in this and many other clinical scenarios; yet their impact on cardiometabolic health has not been elucidated. The objective of this review was to summarize current views on the pharmacology of SSRIs and cardiometabolic risk, as well as available epidemiological evidence regarding its clinical significance. SSRIs appear to intervene in cardiometabolic physiology fundamentally by modulating chronic inflammation, a key pathophysiologic phenomenon in MS, DM2 and CVD. However, the dosing necessary to achieve a beneficial impact in this regard, as well as their clinical correlations, remain controversial. Each SSRI displays a particular profile regarding each of the components of the MS: weight gain seems to be the most common effect of SSRIs, more frequent with paroxetine, followed by citalopram and escitalopram. As a drug class, SSRIs also appear to promote hypercholesterolemia rather uniformly, while fluoxetine and citalopram appear to particularly increase triacylglyceride levels. In contrast, fluvoxamine and paroxetine seem to have the greatest impact on dysglycemia. Lastly, most SSRIs appear to be innocuous or even beneficial regarding blood pressure and high-density lipoprotein cholesterol. Nevertheless, many of these effects may vary significantly upon specific clinical circumstances, especially timing. This topic remains rather unexplored in clinical psychopharmacology, and further, larger-scale epidemiological studies are needed in order to offer improved care in this field.

show abstract

“…SSRIs increase the risk of weight gain and metabolic syndrome (Dannon et al, 2007;Fava, 2000;Kivimäjum et al, 2010;Raeder, Bjelland, Vollset, & Steen, 2006;Serreti & Mandelli, 2010). Type II diabetes is considered an inflammatory condition and SSRIS increase the risk of Type II diabetes (Andersohn, Schade, Suissa, & Garbe, 2009;Kivimäjum et al, 2010;Rubin et al, 2010). Long term antidepressants increase inflammatory markers such as CRP (Hamer et al, 2011), a predictor of heart attacks.…”

Section: Adverse Effects Long Termmentioning

confidence: 99%

The Controversy Over Antidepressant Drugs in an Era of Evidence-Based Practice

Littrell

Lacasse

2012

Social Work in Mental Health

View full text Add to dashboard Cite

Long-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus

Abstract: Long-term use of antidepressants in at least moderate daily doses was associated with an increased risk of diabetes. This association was observed for both tricyclic antidepressants and selective serotonin reuptake inhibitors.

Cited by 257 publications

References 39 publications

Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity

Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity

Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors: are the metabolic syndrome and an increase in cardiovascular risk unavoidable?

The Controversy Over Antidepressant Drugs in an Era of Evidence-Based Practice

Contact Info

Product

Resources

About